Related Experiment Video
Updated: Sep 28, 2025

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway
Xue Tian1, Xu Chen2, Qianqian Jiang1
1School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
Abstract:
Aims: Cardiac lipotoxicity is the common consequence of lipid metabolism disorders in cardiomyocytes during development of heart failure (HF). Adenosine 5'monophosphate-activated protein kinase (AMPK) acts as an energy sensor and has a beneficial effect in reducing lipotoxicity. Notoginsenoside R1 (NGR1) is extracted from the traditional Chinese medicine Panax notoginseng (Burkill) F.H.Chen (P. notoginseng) and has definite cardioprotective effects. However, whether NGR1 can attenuate HF by mitigating lipotoxicity has not been elucidated yet. This study aimed to explore whether NGR1 plays a protective role against HF by ameliorating cardiac lipotoxicity via the AMPK pathway. Methods: In this study, HF mice model was established by left anterior descending (LAD) ligation. palmitic acid (PA) stimulated H9C2 cell model was applied to clarify the effects and potential mechanism of NGR1 on lipotoxicity. In vivo, NGR1 (7.14 mg/kg/days) and positive drug (simvastatin: 2.9 mg/kg/days) were orally administered for 14 days. Echocardiography was applied to assess heart functions. Lipid levels were measured by Enzyme-linked immunosorbent assay (ELISA) and key proteins in the AMPK pathway were detected by western blots. In vitro, NGR1 (40 μmol/L) or Compound C (an inhibitor of AMPK, 10 μmol/L) was co-cultured with PA stimulation for 24 h in H9C2 cells. CCK-8 assay was used to detect cell viability. Key lipotoxicity-related proteins were detected by western blots and the LipidTOX™ neutral lipid stains were used to assess lipid accumulation. In addition, Apoptosis was assessed by Hoechst/PI staining. Results: NGR1 could significantly improve the cardiac function and myocardial injury in mice with HF and up-regulate the expression of p-AMPK. Impressively, NGR1 inhibited the synthesis of diacylglycerol (DAG) and ceramide and promoted fatty acid oxidation (FAO) in vivo. Moreover, NGR1 significantly promoted expression of CPT-1A, the key enzyme in FAO pathway, and down-regulated the expression of GPAT and SPT, which were the key enzymes catalyzing production of DAG and ceramide. In vitro experiments showed that NGR1 could significantly attenuate lipid accumulation in PA-induced H9C2 cells and the Hoechst/PI staining results showed that NGR1 ameliorated lipotoxicity-induced apoptosis in PA-stimulated H9C2 cell model. Furthermore, co-treatment with inhibitor of AMPK abrogated the protective effects of NGR1. The regulative effects of NGR1 on lipid metabolism were also reversed by AMPK inhibitor. Conclusion: NGR1 could significantly improve the heart function of mice with HF and reduce cardiac lipotoxicity. The cardio-protective effects of NGR1 are mediated by the activation of AMPK pathway.
Insights
Notoginsenoside R1 (NGR1) improves heart function in heart failure (HF) by reducing cardiac lipotoxicity. This protection is achieved through activating the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway, enhancing fatty acid oxidation, and inhibiting harmful lipid synthesis.
Area of Science:
- Cardiovascular Biology
- Metabolic Disorders
- Pharmacology
Background:
- Cardiac lipotoxicity, stemming from lipid metabolism disorders, is a key factor in heart failure (HF) development.
- Adenosine 5'monophosphate-activated protein kinase (AMPK) is an energy sensor with known beneficial effects in mitigating lipotoxicity.
- Notoginsenoside R1 (NGR1), derived from Panax notoginseng, exhibits cardioprotective properties, but its role in mitigating HF via lipotoxicity was unexplored.
Purpose of the Study:
- To investigate the potential protective role of NGR1 against heart failure (HF).
- To determine if NGR1 ameliorates cardiac lipotoxicity.
- To elucidate the underlying mechanism involving the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway.
Main Methods:
- Established HF in mice using left anterior descending (LAD) ligation; treated with NGR1 or simvastatin.
- Utilized palmitic acid (PA)-stimulated H9C2 cells to model cardiac lipotoxicity and assess NGR1 effects.
- Evaluated cardiac function via echocardiography, measured lipid levels (ELISA), and analyzed protein expression (Western blot) for AMPK pathway and lipotoxicity markers. Assessed cell viability (CCK-8), lipid accumulation (LipidTOX™), and apoptosis (Hoechst/PI staining) in vitro.
Main Results:
- NGR1 significantly improved cardiac function and reduced myocardial injury in HF mice, concurrently up-regulating p-AMPK expression.
- NGR1 inhibited diacylglycerol (DAG) and ceramide synthesis while promoting fatty acid oxidation (FAO) by up-regulating CPT-1A and down-regulating GPAT and SPT.
- In vitro, NGR1 attenuated PA-induced lipid accumulation and apoptosis in H9C2 cells; these effects were reversed by an AMPK inhibitor, confirming pathway involvement.
Conclusions:
- Notoginsenoside R1 (NGR1) demonstrates significant efficacy in improving heart function and reducing cardiac lipotoxicity in a heart failure (HF) model.
- The cardioprotective effects of NGR1 are mediated through the activation of the Adenosine 5'monophosphate-activated protein kinase (AMPK) pathway.
- NGR1 modulates lipid metabolism by promoting fatty acid oxidation and inhibiting de novo lipogenesis, offering a potential therapeutic strategy for HF.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
cAMP-dependent Protein Kinase Pathways
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

